Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial

guest :: login JuSER
		Search		Submit		Personalize Your alerts Your baskets Your searches		Help

Home > Publications database > Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial > Access to Fulltext

Information
Discussion
Files
Plots

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial - FZJ-2019-01486

Main document file(s):

Similar records

JuSER :: :: :: ::
Powered by v1.1.7 |
Maintained by

Impressum | Data Privacy Policy

This site is also available in the following languages:
Deutsch English